ROQA.F logo

Coiled Therapeutics plcOTCPK:ROQA.F Stock Report

Market Cap US$51.4m
Share Price
US$0.15
My Fair Value
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Coiled Therapeutics plc

OTCPK:ROQA.F Stock Report

Market Cap: US$51.4m

Coiled Therapeutics (ROQA.F) Stock Overview

A clinical stage oncology company, develops precision oncology therapies. More details

ROQA.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap ($38M)


ROQA.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 69.2% undervalued intrinsic discount
5419.8%Revenue growth p.a.
5.8k
17
0
113
2mo ago

Coiled Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Coiled Therapeutics
Historical stock prices
Current Share PriceUK£0.15
52 Week HighUK£0.21
52 Week LowUK£0.15
Beta0
1 Month Change-8.98%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.33%

Recent News & Updates

Recent updates

Shareholder Returns

ROQA.FUS BiotechsUS Market
7D0%0.2%3.1%
1Yn/a37.8%27.4%

Return vs Industry: Insufficient data to determine how ROQA.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ROQA.F performed against the US Market.

Price Volatility

Is ROQA.F's price volatile compared to industry and market?
ROQA.F volatility
ROQA.F Average Weekly Movementn/a
Biotechs Industry Average Movement10.7%
Market Average Movement7.1%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.3%

Stable Share Price: ROQA.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ROQA.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSridhar Vempaticoiledplc.com

Coiled Therapeutics plc, a clinical stage oncology company, develops precision oncology therapies. It develops AO-252, a TACC3 inhibitor that is in Phase I clinical trials; and STAT-6 siRNA program, which is in preclinical trials for treating immunology indications. The company is based in London, United Kingdom.

Coiled Therapeutics plc Fundamentals Summary

How do Coiled Therapeutics's earnings and revenue compare to its market cap?
ROQA.F fundamental statistics
Market capUS$51.38m
Earnings (TTM)US$0
Revenue (TTM)n/a
n/a
P/E Ratio
n/a
P/S Ratio

Is ROQA.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROQA.F income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$0
EarningsUS$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did ROQA.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/13 15:55
End of Day Share Price 2026/03/17 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coiled Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.